company background image
BLAU

Blau Farmacêutica BOVESPA:BLAU3 Stock Report

Last Price

R$25.06

Market Cap

R$4.5b

7D

2.4%

1Y

-48.3%

Updated

30 Jun, 2022

Data

Company Financials +
BLAU3 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends2/6

BLAU3 Stock Overview

Blau Farmacêutica S.A., a pharmaceutical company, engages in the manufacture, development, and commercialization of private label drugs in Brazil, Colombia, Uruguay, Chile, and internationally.

Blau Farmacêutica Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Blau Farmacêutica
Historical stock prices
Current Share PriceR$25.06
52 Week HighR$54.92
52 Week LowR$21.55
Beta0
1 Month Change5.21%
3 Month Change-13.56%
1 Year Change-48.25%
3 Year Changen/a
5 Year Changen/a
Change since IPO-39.03%

Recent News & Updates

Feb 24
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Blau Farmacêutica S.A. ( BVMF:BLAU3 ) shareholders are probably feeling a little disappointed, since its shares fell...

Shareholder Returns

BLAU3BR BiotechsBR Market
7D2.4%0.4%-0.1%
1Y-48.3%-27.9%-29.3%

Return vs Industry: BLAU3 underperformed the BR Biotechs industry which returned -27.3% over the past year.

Return vs Market: BLAU3 underperformed the BR Market which returned -29.1% over the past year.

Price Volatility

Is BLAU3's price volatile compared to industry and market?
BLAU3 volatility
BLAU3 Average Weekly Movement5.6%
Biotechs Industry Average Movement10.6%
Market Average Movement5.9%
10% most volatile stocks in BR Market9.2%
10% least volatile stocks in BR Market2.9%

Stable Share Price: BLAU3 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BLAU3's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19871,300Marcelo Hahnhttps://www.blau.com

Blau Farmacêutica S.A., a pharmaceutical company, engages in the manufacture, development, and commercialization of private label drugs in Brazil, Colombia, Uruguay, Chile, and internationally. It operates through Institutional and Retail segments. The company’s medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics.

Blau Farmacêutica Fundamentals Summary

How do Blau Farmacêutica's earnings and revenue compare to its market cap?
BLAU3 fundamental statistics
Market CapR$4.50b
Earnings (TTM)R$300.52m
Revenue (TTM)R$1.35b

15.0x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLAU3 income statement (TTM)
RevenueR$1.35b
Cost of RevenueR$697.09m
Gross ProfitR$656.54m
Other ExpensesR$356.02m
EarningsR$300.52m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.68
Gross Margin48.50%
Net Profit Margin22.20%
Debt/Equity Ratio19.2%

How did BLAU3 perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

9%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is BLAU3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLAU3?

Other financial metrics that can be useful for relative valuation.

BLAU3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA8.7x
PEG Ratio0.9x

Price to Earnings Ratio vs Peers

How does BLAU3's PE Ratio compare to its peers?

BLAU3 PE Ratio vs Peers
The above table shows the PE ratio for BLAU3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average18.9x
OFSA3 Ouro Fino Saúde Animal Participações
8.9xn/aR$1.1b
002880 Shenzhen Weiguang Biological Products
29.2xn/aCN¥6.0b
HYPE3 Hypera
14.5x18.2%R$24.0b
A145020 Hugel
22.9x25.4%₩1.2t
BLAU3 Blau Farmacêutica
15x16.6%R$4.5b

Price-To-Earnings vs Peers: BLAU3 is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (18.9x).


Price to Earnings Ratio vs Industry

How does BLAU3's PE Ratio compare vs other companies in the Global Biotechs Industry?

Price-To-Earnings vs Industry: BLAU3 is good value based on its Price-To-Earnings Ratio (15x) compared to the Global Biotechs industry average (26.9x)


Price to Earnings Ratio vs Fair Ratio

What is BLAU3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLAU3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15x
Fair PE Ratio14.1x

Price-To-Earnings vs Fair Ratio: BLAU3 is expensive based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (14.1x).


Share Price vs Fair Value

What is the Fair Price of BLAU3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BLAU3 (R$25.06) is trading above our estimate of fair value (R$20.67)

Significantly Below Fair Value: BLAU3 is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: BLAU3 is good value based on its PEG Ratio (0.9x)


Discover undervalued companies

Future Growth

How is Blau Farmacêutica forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLAU3's forecast earnings growth (16.6% per year) is above the savings rate (9.2%).

Earnings vs Market: BLAU3's earnings (16.6% per year) are forecast to grow faster than the BR market (6.6% per year).

High Growth Earnings: BLAU3's earnings are forecast to grow, but not significantly.

Revenue vs Market: BLAU3's revenue (16.4% per year) is forecast to grow faster than the BR market (5.6% per year).

High Growth Revenue: BLAU3's revenue (16.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BLAU3's Return on Equity is forecast to be high in 3 years time (22.5%)


Discover growth companies

Past Performance

How has Blau Farmacêutica performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


31.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BLAU3 has a high level of non-cash earnings.

Growing Profit Margin: BLAU3's current net profit margins (22.2%) are lower than last year (24%).


Past Earnings Growth Analysis

Earnings Trend: BLAU3's earnings have grown significantly by 31.5% per year over the past 5 years.

Accelerating Growth: BLAU3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BLAU3 had negative earnings growth (-2.8%) over the past year, making it difficult to compare to the Biotechs industry average (8.2%).


Return on Equity

High ROE: BLAU3's Return on Equity (18%) is considered low.


Discover strong past performing companies

Financial Health

How is Blau Farmacêutica's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its short term liabilities (R$302.9M).

Long Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its long term liabilities (R$332.7M).


Debt to Equity History and Analysis

Debt Level: BLAU3 has more cash than its total debt.

Reducing Debt: BLAU3's debt to equity ratio has reduced from 123% to 19.2% over the past 5 years.

Debt Coverage: BLAU3's debt is well covered by operating cash flow (43%).

Interest Coverage: BLAU3 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Blau Farmacêutica current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.81%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: BLAU3's dividend (1.81%) is higher than the bottom 25% of dividend payers in the BR market (1.76%).

High Dividend: BLAU3's dividend (1.81%) is low compared to the top 25% of dividend payers in the BR market (7.89%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether BLAU3's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if BLAU3's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (8.7%), BLAU3's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: BLAU3 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Marcelo Hahn

no data

Tenure

Mr. Marcelo Rodolfo Hahn is the Founder and serves as Chief Executive Officer at Blau Farmacêutica S/A and serves as its Deputy Chairman of the Board. Mr. Hahn served as President at Blau Farmacêutica S/A.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Blau Farmacêutica S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Blau Farmacêutica S.A.
  • Ticker: BLAU3
  • Exchange: BOVESPA
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: R$4.496b
  • Shares outstanding: 179.39m
  • Website: https://www.blau.com

Number of Employees


Location

  • Blau Farmacêutica S.A.
  • Rodovia Raposo Tavares, 2833, km 30,5
  • Barro Branco
  • Cotia
  • São Paulo
  • 06705-030
  • Brazil

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.